WallStreetZenWallStreetZen

NASDAQ: GRTS
Gritstone Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for GRTS

Based on 3 analysts offering 12 month price targets for Gritstone Bio Inc.
Min Forecast
$3.00+361.54%
Avg Forecast
$4.00+515.38%
Max Forecast
$5.00+669.23%

Should I buy or sell GRTS stock?

Based on 3 analysts offering ratings for Gritstone Bio Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GRTS stock forecasts and price targets.

GRTS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-14
lockedlocked$00.00+00.00%2024-05-24
lockedlocked$00.00+00.00%2024-05-13

1 of 1

Forecast return on equity

Is GRTS forecast to generate an efficient return?
Company
-435.4%
Industry
73.55%
Market
80.58%
GRTS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GRTS forecast to generate an efficient return on assets?
Company
-44.31%
Industry
31.45%
GRTS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GRTS earnings per share forecast

What is GRTS's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.99
Avg 2 year Forecast
-$0.87
Avg 3 year Forecast
-$0.78

GRTS revenue forecast

What is GRTS's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$52.4M+234.93%
Avg 2 year Forecast
$86.4M+452.04%
Avg 3 year Forecast
$21.5M+37.26%
GRTS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GRTS revenue growth forecast

How is GRTS forecast to perform vs Biotechnology companies and vs the US market?
Company
41.46%
Industry
37.21%
Market
10.62%
GRTS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GRTS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GRTS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GRTS$0.65$4.00+515.38%Strong Buy
MNOV$1.44N/AN/A
DTIL$10.13$39.50+289.93%Strong Buy
INTS$5.09$12.00+135.76%Buy
CVM$1.28N/AN/A

Gritstone Bio Stock Forecast FAQ

Is Gritstone Bio Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: GRTS) stock is to Strong Buy GRTS stock.

Out of 3 analysts, 1 (33.33%) are recommending GRTS as a Strong Buy, 2 (66.67%) are recommending GRTS as a Buy, 0 (0%) are recommending GRTS as a Hold, 0 (0%) are recommending GRTS as a Sell, and 0 (0%) are recommending GRTS as a Strong Sell.

If you're new to stock investing, here's how to buy Gritstone Bio stock.

What is GRTS's earnings growth forecast for 2024-2026?

(NASDAQ: GRTS) Gritstone Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.78%.

Gritstone Bio's earnings in 2024 is -$144,893,000.On average, 4 Wall Street analysts forecast GRTS's earnings for 2024 to be -$107,483,680, with the lowest GRTS earnings forecast at -$119,426,311, and the highest GRTS earnings forecast at -$92,283,968. On average, 4 Wall Street analysts forecast GRTS's earnings for 2025 to be -$93,912,509, with the lowest GRTS earnings forecast at -$119,426,311, and the highest GRTS earnings forecast at -$74,912,868.

In 2026, GRTS is forecast to generate -$84,684,112 in earnings, with the lowest earnings forecast at -$84,684,112 and the highest earnings forecast at -$84,684,112.

What is GRTS's revenue growth forecast for 2024-2026?

(NASDAQ: GRTS) Gritstone Bio's forecast annual revenue growth rate of 41.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.62%.

Gritstone Bio's revenue in 2024 is $15,645,000.On average, 3 Wall Street analysts forecast GRTS's revenue for 2024 to be $5,689,035,198, with the lowest GRTS revenue forecast at $1,704,539,172, and the highest GRTS revenue forecast at $12,919,755,506. On average, 3 Wall Street analysts forecast GRTS's revenue for 2025 to be $9,376,702,555, with the lowest GRTS revenue forecast at $770,842,555, and the highest GRTS revenue forecast at $24,102,401,028.

In 2026, GRTS is forecast to generate $2,331,527,307 in revenue, with the lowest revenue forecast at $863,126,523 and the highest revenue forecast at $3,799,928,090.

What is GRTS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GRTS) forecast ROA is -44.31%, which is lower than the forecast US Biotechnology industry average of 31.45%.

What is GRTS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year GRTS price target, the average GRTS price target is $4.00, with the highest GRTS stock price forecast at $5.00 and the lowest GRTS stock price forecast at $3.00.

On average, Wall Street analysts predict that Gritstone Bio's share price could reach $4.00 by Jun 14, 2025. The average Gritstone Bio stock price prediction forecasts a potential upside of 515.38% from the current GRTS share price of $0.65.

What is GRTS's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: GRTS) Gritstone Bio's current Earnings Per Share (EPS) is -$1.24. On average, analysts forecast that GRTS's EPS will be -$0.99 for 2024, with the lowest EPS forecast at -$1.10, and the highest EPS forecast at -$0.85. On average, analysts forecast that GRTS's EPS will be -$0.87 for 2025, with the lowest EPS forecast at -$1.10, and the highest EPS forecast at -$0.69. In 2026, GRTS's EPS is forecast to hit -$0.78 (min: -$0.78, max: -$0.78).

What is GRTS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GRTS) forecast ROE is -435.4%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.